At a glance
- Originator Genentech
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 01 Dec 1995 New profile
- 01 Dec 1995 Phase-I clinical trials for Thrombosis in Switzerland (Unknown route)
- 01 Dec 1995 Phase-I clinical trials for Thrombosis in USA (Unknown route)